Treatment response to topical dorzolamide and visual function in cystoid macular edema secondary to retinitis pigmentosa

Abstract

Purpose : To investigate the relationships between the response of cystoid macular edema secondary to retinitis pigmentosa (RP-CME) to topical dorzolamide and visual outcome.
We retrospectively reviewed the examination results of patients with RP-CME who were treated at Kyushu University Hospital. Sixty-nine eyes of 47 patients who consecutively underwent at least three Humphrey Field Analyzer (HFA) using a central 10-2 Swedish interactive thresholding algorithm were included. RP-CME were treated with 1.0% topical dorzolamide, and classified into 2 groups based on treatment response. The responder to treatment was defined as 1) more than 20% reduction of central subfield thickness (CST) from the baseline or 2) resolution of cysts within 12 months from treatment initiation.

Methods : We retrospectively reviewed the examination results of patients with RP-CME who were treated at Kyushu University Hospital. Sixty-nine eyes of 47 patients who consecutively underwent at least three Humphrey Field Analyzer (HFA) using a central 10-2 Swedish interactive thresholding algorithm were included. RP-CME were treated with 1.0% topical dorzolamide, and classified into 2 groups based on treatment response. The responder to treatment was defined as 1) more than 20% reduction of central subfield thickness (CST) from the baseline or 2) resolution of cysts within 12 months from treatment initiation.

Results : The average follow-up period was 3.8 years. The number of RP-CME which showed response to topical dorzolamide (responder) and those which did not respond (non-responder) was 42 and 27, respectively. The slope for decline in macular sensitivity and foveal sensitivity in HFA 10-2 tests were significantly steeper in non-responder compared with responder (p=0.001, p=0.002 respectively). MD slope was not significantly different between the 2 groups (p=0.53).

Conclusions : Reduction/resolution of CME by topical dorzolamide may attenuateed the visual sensitivity loss and preserve the central visual function in RP-CME patients.

This is a 2020 ARVO Annual Meeting abstract.